ZYNE - Zynerba Pharmaceutic...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $4.46 | Open | $4.49 |
| Volume | 1.57M | Market Cap | 131.3M |
| Yield | Last Dividend |
| Cannabis Stock Gainers And Losers From F... | 02/18/21 |
| GAINERS: Primo Nutraceuticals (PINK: BUGVF ) shares closed up 313.22% at $2.50 Learn more Origin Agritech (NASDAQ: SEED ) shares closed up 16.39% at $... | |
| The Daily Biotech Pulse: DermTech Soars ... | 02/11/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X... | |
| 94 Biggest Movers From Yesterday | 02/11/21 |
| Gainers Anchiano Therapeutics Ltd. (NASDAQ: ANCN ) jumped 187.4% to close at $7.96. Bio-Path Holdings, Inc. (NASDAQ: BPTH ) shares surged 126.4% to cl... | |
| Cannabis Stock Gainers And Losers From F... | 02/03/21 |
| GAINERS: Medical Marijuana Inc (PINK: MJNA ) shares closed up 36.30% at $0.04 Reliq Health Technologies Inc (PINK: RQHTF ) shares closed up 33.62% at ... | |
| Zynerba Pharmaceuticals : December, 2020... | 01/02/21 |
| Phase 2 ongoing Autism spectrum disorder - Phase 2 complete Developmental and epileptic encephalopathies -??? | January 2, 2021 | |
| Shuman, Glenn & Stecker Investigates Zyn... | 12/09/20 |
| Shuman, Glenn & Stecker announces that it is investigating potential claims against certain officers and directors of Zynerba Pharmaceuticals, Inc. (?... | |
| The Law Offices of Frank R. Cruz Announc... | 12/07/20 |
| LOS ANGELES--(BUSINESS WIRE)---- $ZYNE #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors... | |
| FXNEWS24 |NA Proactive news snapshot: Zy... | 12/04/20 |
| NA Proactive news snapshot: Zynerba Pharmaceuticals, Pure Gold Mining, OTC Markets Group, KushCo Holdings UPDATE??? | UK Stocks, Forex, Commodities, C... | |
| Zynerba Pharmaceuticals Announces the Ac... | 11/23/20 |
| DEVON, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transder... | |
| The Week In Cannabis: Stocks Down Amid E... | 11/14/20 |
| Cannabis stocks were back in the red this week, retreating from post-election highs amid an earnings-heavy period. Over the five trading days of the w... | |
| Earnings Update: Aurora, Canopy Growth, ... | 11/09/20 |
| Aurora Posts Q1 EBITDA Loss, Expects Positive EBITDA In Q2 Aurora Cannabis Inc. (NYSE: ACB ) (TSX: ACB) consolidated net revenue of CA$67.8 million ($... | |
| Zynerba Pharmaceuticals Does Earnings Su... | 11/04/20 |
| Zynerba Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by?... | |
| Zynerba Pharmaceuticals, Inc. (NASDAQ:ZY... | 10/21/20 |
| Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has been assigned an average rating of ???Buy??? from the eight brokerages that are covering the stock, Ma... | |
| Cannabis Pharmaceuticals Market Signific... | 10/19/20 |
| The proposed Cannabis Pharmaceuticals Market report will encompass all the qualitative & quantitative aspects including the market size, market estima... | |
| Cannabis Stock Gainers And Losers From O... | 10/15/20 |
| GAINERS: Rhinomed (OTCQB: RHNMF ) shares closed up 38.32% at $0.15 ReneSola (NYSE: SOL ) shares closed up 14.84% at $4.18 BioHarvest Sciences (PINK: C... | |
| Making The Case For Zynerba Pharmaceutic... | 09/17/20 |
| Zynerba's Pivotal Phase 3 CONNECT-FX study is the first placebo-controlled study to show statistical significance in children with Fragile X Syndrome ... | |
| Zynerba's cannabidiol an Orphan drug for... | 09/17/20 |
| The FDA has granted Orphan drug status for Zynerba's (ZYNE +6.2%) cannabidiol as a treatment of 22q.11.2 deletion syndrome, according to a post to the... | |
| Zynerba Pharmaceuticals : August, 2020 C... | 08/10/20 |
| pivotal trial complete Developmental and epileptic encephalopathies - Phase 2 complete Autism spectrum??? | August 10, 2020 | |
| Zynerba Pharmaceuticals Reports Second Q... | 08/10/20 |
| DEVON, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transder... | |
| Cannabis Stock Gainers And Losers From A... | 08/04/20 |
| Gainers: MGC Pharmaceuticals (OTC: MGCLF ) shares closed up 72.5% at $0.04 Heritage Cannabis Holding (OTC: HERTF ) shares closed up 20.97% at $0.08 Ti... | |
| Zynerba Pharmaceuticals to Present an Up... | 07/22/20 |
| - New Data Show Statistically Significant Improvements in Caregiver Impression of Change in Fragile X Behaviors Including Social Avoidance in Patients... | |
| The Week In Cannabis: Stocks Underperfor... | 07/05/20 |
| It was a relatively quiet week ahead of the Fourth of July. Nonetheless, a handful of announcements had the cannabis markets buzzing. Zynerba Pharmace... | |
| Cannabis Stock Gainers And Losers From J... | 07/01/20 |
| Gainers CordovaCann (OTC: LVRLF ) shares closed up 25.61% at $0.30 Axim Biotechnologies (OTC: AXIM ) shares closed up 15.24% at $0.31 Cansortium (OTC:... | |
| Analysts Offer Insights on Healthcare Co... | 07/01/20 |
| There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Catasys (CATS), Akero Therapeutics (AKRO) and Zynerba | |
| Synthetic Cannabinoid Drug Maker Zynerba... | 06/30/20 |
| Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) shares retreated to their lowest level since early April following a clinical readout from the company. Wh... | |
| Zynerba plummets 51% after its CBD gel f... | 06/30/20 |
| Zynerba, a small biotechnology company, plummeted 51% on Tuesday after its CBD gel failed a pivotal trial for a rare disorder called Fragile X syndrom... | |
| ViewRay and NantKwest among healthcare g... | 06/30/20 |
| Gainers: Calliditas Therapeutics (NASDAQ:CALT) +20%. ViewRay (NASDAQ:VRAY) +19%. Anixa Biosciences (NASDAQ:ANIX) +19%. OptiNose (NASDAQ:OPTN) +18%. Na... | |
| Zynerba's Zygel flunks Fragile X study (... | 06/30/20 |
| Zynerba Pharmaceuticals (NASDAQ:ZYNE) is poised for a significant down move today after reporting unsuccessful results from a 245-subject Phase 2/3 cl... | |
| Zynerba Pharmaceuticals Announces Top Li... | 06/30/20 |
| - Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set - - Achieved Statistical Significance on??... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Biotech picks | mr jackson | 50.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
